Patents Examined by Elizabeth C. Kemmerer
  • Patent number: 12292442
    Abstract: Provided are a monoclonal antibody against CD19 antibody and the application thereof. The monoclonal antibody which targets CD 19 antibody has high specificity and strong affinity. Also provided are a detection reagent with high sensitivity, good accuracy and good specificity for the detection of CAR-T cells and a detection method using the detection reagent, which may directly target an extracellular antigen-binding region on the CAR-T cell.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: May 6, 2025
    Assignee: BIOSWAN LABORATORIES, INC.
    Inventor: Liang Da
  • Patent number: 12285755
    Abstract: Described herein are clinical diagnostics and more specifically to a lateral-flow assay devices.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: April 29, 2025
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Zhong Ding, Edward R. Scalice, Philip C. Hosimer
  • Patent number: 12281297
    Abstract: The present disclosure is directed to systems and methods for sampling and/or controlling the productivity of a bioreactor. The system and methods can include a vessel capable of providing an environment suitable for containing whole broth that can produce the bioproduct, wherein the whole broth contains media and at least one undissolved species, an automated sampling system, a first analytical instrument, and a control system.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: April 22, 2025
    Assignee: EMD Millipore Corporation
    Inventors: Roderick J. Ray, Adam S. Carroll, Brandon J. Downey, Lisa J. Graham
  • Patent number: 12276663
    Abstract: Methods of detecting a human leukocyte antigen (HLA)-A*32:01 allele in a subject as disclosed are useful, for example, to determine whether the subject is at risk for developing or has vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Methods of treating bacterial infection in a subject with vancomycin-induced DRESS are also disclosed.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 15, 2025
    Assignee: Vanderbilt University
    Inventors: Elizabeth Phillips, Simon Mallal, Katherine Konvinse, Abha Chopra
  • Patent number: 12275792
    Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: April 15, 2025
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos
  • Patent number: 12265086
    Abstract: Methods of identifying an individual as being a slow gingivitis responder or a high gingivitis responder are disclosed. Some methods are based on IL-1? levels in the individual's GCF at the site of inflammation. Some methods are based on MIF and/or CCL-1 levels in the individual's GCF in healthy tissue distant from the site of inflammation. Some disclosed methods are based on temporal differences in IL-8, IL-6 and/or TNF? levels in the individual's GCF in healthy tissue distant from the site of inflammation during the development of plaque induced inflammation. Methods of treating an individual who has gingivitis and methods of preventing gingivitis are also provided. The treatment and prevention methods comprise determining if individual is a slow gingivitis responder or a high gingivitis responder and applying oral care compositions to the individual's oral cavity.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: April 1, 2025
    Assignee: Colgate-Palmolive Company
    Inventors: Dandan Chen, Harsh Mahendra Trivedi, James Masters, Richard P. Darveau, Jeffrey S. Mclean
  • Patent number: 12265092
    Abstract: The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 1, 2025
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Aline Pehla, Darius Wilson
  • Patent number: 12258391
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: March 25, 2025
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Patent number: 12252546
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: March 18, 2025
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
  • Patent number: 12233094
    Abstract: The present disclosure is directed to systems, methods, and compositions for functional interaction of fibroblasts with one or more types of immune cells such that the interaction results in modification to the fibroblasts, the one or more types of immune cells, or both. In some embodiments, one or more certain agents are also utilized during the interaction or in lieu of one of the types of cells. In specific embodiments, cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: February 25, 2025
    Assignee: Spinalcyte, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Patent number: 12234282
    Abstract: The invention provides compositions and methods for treating optic neuropathic disorders.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: February 25, 2025
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Dong Feng Chen, Ji Min, Kin-Sang Cho
  • Patent number: 12233104
    Abstract: In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2R?-selective agonist and the long-acting, IL-15 moiety.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 25, 2025
    Assignee: Nektar Therapeutics
    Inventors: Deborah H. Charych, Peter Benedict Kirk
  • Patent number: 12227564
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: February 18, 2025
    Assignee: PFIZER INC.
    Inventors: Kevin Charles Beaumont, Danna M. Breen, Matthew Allister Lambert, Jeffrey Raymond Chabot, Tao He, Ksenya Shchors, James R. Apgar
  • Patent number: 12227581
    Abstract: A group of anti-BCMA single domain antibodies, as well as genes of the single domain antibodies in the group, a vector containing the single domain antibodies in the group, a chimeric antigen receptor, and a T cell modified by a chimeric antigen receptor, and detection and treatment application of the single domain antibodies in the group. The anti-BCMA single domain antibodies have high activity, high stability, high specificity, and high binding capability.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 18, 2025
    Assignee: SHENZHEN PREGENE BIOPHARMA CO., LTD.
    Inventors: Jishuai Zhang, Hongjian Li, Chaolemeng Bao, Qinghua Cai, Yingying Li, Zongpei Song, Yijin Ding, Zhibo Cai
  • Patent number: 12228570
    Abstract: The present invention relates to methods for determining the quantity of an analyte in sample using lateral flow strips comprising highly-doped upconversion nanoparticles.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: February 18, 2025
    Assignee: UNIVERSITY OF TECHNOLOGY SYDNEY
    Inventors: Dayong Jin, Hao He
  • Patent number: 12227582
    Abstract: The present disclosure provides isolated binding molecules that bind to and activates CD137, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: February 18, 2025
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventors: Aaron Kurtzman, Hieu Tran, Shihao Chen
  • Patent number: 12221476
    Abstract: The present invention relates to an antibody or antigen binding fragment thereof that binds specifically to IGFBP3 and does not displace the binding of IGF-I to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: February 11, 2025
    Assignees: OSPEDALE SAN RAFFAELE S.R.L., ENTHERA S.R.L.
    Inventors: Paolo Fiorina, Francesca D'Addio, Francesca Zagari
  • Patent number: 12215171
    Abstract: This disclosure anti-human IgG antibodies and antigen-binding portions thereof derived from rabbits and methods of using these antibodies and portions.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: February 4, 2025
    Assignee: Genzyme Corporation
    Inventor: Ruiyin Chu
  • Patent number: 12214014
    Abstract: This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new dermal adipocytes (DAs). Methods described herein comprise (a) grafting of human hair follicles or (b) direct delivery of conditioned media from in vitro cultured hair follicles, or (c) delivery of purified individual factors secreted by hair follicles, or (d) delivery of small molecule agonists that mimic hair derived signaling activities, or (e) delivery of small molecule antagonists that inhibit anti-adipogenic programs, or (f) delivery of small molecule agonists of pro-adipogenic programs to convert endogenous wound or scar skin fibroblasts into new DAs.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: February 4, 2025
    Assignees: The Trustees of the University of Pennsylvania, The Regents of the University of California
    Inventors: George Cotsarelis, Christian F. Guerrero-Juarez, Maksim Plikus
  • Patent number: 12213997
    Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for the generation of a supporting matrix for cells, such as stem cells and NP cells (and precursors thereof). For example, an NP cell-specific phenotype precursor cell can be an adult NP cell, such as a cell taken from the adult and degenerated intervertebral disc and/or a progenitor cell, such as stem cells, induced pluripotent cells, pluripotent cells, precursor cells, or stromal cells.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: February 4, 2025
    Assignee: Washington University
    Inventors: Lori Setton, Marcos Barcellona, Julie Speer